Literature DB >> 7989128

Chimeric transcripts with an open reading frame are generated as a result of translocation to the Pvt-1 region in mouse B-cell tumors.

K Huppi1, D Siwarski.   

Abstract

Some mouse plasmacytomas exhibit a t(6;15) chromosomal translocation in which the breakpoint resides within the Pvt-1 locus located 260 kilobases (kb) downstream of c-myc on mouse chromosome 15. In this report, we show that the Pvt-1 locus does not exhibit allelic exclusion in that Pvt-1 transcripts continue to be expressed from the non-translocated allele in t(6;15) plasmacytomas. From the translocated allele, we find chimeric transcripts containing a short 57-bp segment of Pvt-1 (termed Pvt-1a) spliced directly to the immunoglobulin constant region sequence (Ig-Ck). These short transcripts have replaced a Jk segment with a trytophan residue via RNA splicing and contain a continuous open reading frame (ORF) from Pvt-1a through Ck. Since this Pvt-1a/Ck transcript is found in all 3 t(6;15) plasmacytomas examined, regardless of the location of the chromosomal breakpoint, we suggest that the Pvt-1a/Ck chimera may have a functional role in the development of mouse plasmacytomas.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7989128     DOI: 10.1002/ijc.2910590623

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  12 in total

1.  Identification of somatically acquired rearrangements in cancer using genome-wide massively parallel paired-end sequencing.

Authors:  Peter J Campbell; Philip J Stephens; Erin D Pleasance; Sarah O'Meara; Heng Li; Thomas Santarius; Lucy A Stebbings; Catherine Leroy; Sarah Edkins; Claire Hardy; Jon W Teague; Andrew Menzies; Ian Goodhead; Daniel J Turner; Christopher M Clee; Michael A Quail; Antony Cox; Clive Brown; Richard Durbin; Matthew E Hurles; Paul A W Edwards; Graham R Bignell; Michael R Stratton; P Andrew Futreal
Journal:  Nat Genet       Date:  2008-04-27       Impact factor: 38.330

2.  The 8q24 gene desert: an oasis of non-coding transcriptional activity.

Authors:  Konrad Huppi; Jason J Pitt; Brady M Wahlberg; Natasha J Caplen
Journal:  Front Genet       Date:  2012-04-30       Impact factor: 4.599

Review 3.  PVT1: a rising star among oncogenic long noncoding RNAs.

Authors:  Teresa Colombo; Lorenzo Farina; Giuseppe Macino; Paola Paci
Journal:  Biomed Res Int       Date:  2015-03-26       Impact factor: 3.411

4.  The lncRNA PVT1 Contributes to the Cervical Cancer Phenotype and Associates with Poor Patient Prognosis.

Authors:  Marissa Iden; Samantha Fye; Keguo Li; Tamjid Chowdhury; Ramani Ramchandran; Janet S Rader
Journal:  PLoS One       Date:  2016-05-27       Impact factor: 3.240

5.  Role of the long non-coding RNA PVT1 in the dysregulation of the ceRNA-ceRNA network in human breast cancer.

Authors:  Federica Conte; Giulia Fiscon; Matteo Chiara; Teresa Colombo; Lorenzo Farina; Paola Paci
Journal:  PLoS One       Date:  2017-02-10       Impact factor: 3.240

6.  Knockdown of long non-coding RNA PVT1 inhibits the proliferation of Raji cells through cell cycle regulation.

Authors:  Chanli Zheng; Yu Xiao; Yangqiu Li; Dongmei He
Journal:  Oncol Lett       Date:  2019-06-07       Impact factor: 2.967

7.  Oncoviruses and Pathogenic MicroRNAs in Humans.

Authors:  Yoichi Robertus Fujii
Journal:  Open Virol J       Date:  2009-05-07

8.  Pvt1-encoded microRNAs in oncogenesis.

Authors:  Gabriele B Beck-Engeser; Amy M Lum; Konrad Huppi; Natasha J Caplen; Bruce B Wang; Matthias Wabl
Journal:  Retrovirology       Date:  2008-01-14       Impact factor: 4.602

Review 9.  Network-Based Approaches to Explore Complex Biological Systems towards Network Medicine.

Authors:  Giulia Fiscon; Federica Conte; Lorenzo Farina; Paola Paci
Journal:  Genes (Basel)       Date:  2018-08-31       Impact factor: 4.096

Review 10.  Linear and circular PVT1 in hematological malignancies and immune response: two faces of the same coin.

Authors:  Martina Ghetti; Ivan Vannini; Clelia Tiziana Storlazzi; Giovanni Martinelli; Giorgia Simonetti
Journal:  Mol Cancer       Date:  2020-03-30       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.